BRAF and melanoma: Surprisingly, in contrast to the efficacy observed in BRAF-mutant melanoma, BRAF inhibitors were found to activate ERK and stimulate growth of RAS-mutant cancers by an effect known as the RAF inhibitor paradox [37,38].